Andrew Webley

CEO, The Smarter Web Company (@smarterwebuk) | Bitcoin Investor | Previously Head of Online, Hargreaves Lansdown | Posting In A Personal Capacity

[TurboJones @thebizstarter]

Using the android swipe to go back gesture on the right side cause it to select a post icon, if you start the gesture on top of one, instead of going back to the previous page.

The old version provides a safe margin with no action buttons.

I prefer the new side view but not at the expense of back gesture not working consistently.

#NewXAndroidFeedback

[Andrew Webley @asjwebly]

Tell me you know nothing about $HIMS without telling me…

All of the $HIMS bears just see recent headlines and think it’s going to $0

This company has been around since 2017.

It wasn’t until they entered the GLP-1/Weight loss space and started competing with the big pharma wh

[The Wheelie Investor @WheelieInvestor]

I would be surprised if $HIMS is trading above $0 in 2027

[Andrew Webley @asjwebly]

There’s no in between either lol

[Trav @hypergrowth102]

The only difference between $HIMS bulls and bears-

Bulls trust management- and believe they are operating with an ace up their sleeve (me).

Bears think management are liars and frauds- for no apparent reason other than advocating for better pricing and higher quality care.

[Andrew Webley @asjwebly]

A $150 Billion dollar company that only goes up when $HIMS, 3% of the size of $NVO, gets bad news.

[NightHawk Capital @NighthawkTradez]

$NVO likes $HIMS being destroyed

[Andrew Webley @asjwebly]

Stock goes down = dumb investment?

Every stock goes through phases like this, and this time it’s $HIMS

Insulting people for investing in a company they personally believe in — is just weird.

[Midas @midascabal]

$HIMS is the dumbest investment of 2026.

[Andrew Webley @asjwebly]

So you basically just admitted you’re making this post about selling $HIMS for attention…

“I’m selling but not until $50”

“By then the company should be fine so ill probably hold”

Too many people are just engagement farming about selling their $HIMS

It just makes you look b

[Akash @Kajiastic]

This isn’t being emotional, it’s being rational and evaluating my position based on what’s happening right now. I haven’t sold and don’t plan to until my price target of at least $50 is reached. By that point, the narrative around $HIMS could shift again. For now, I’m just holding and watching.

[Andrew Webley @asjwebly]

If the risk and high volatility isn’t for you, then you shouldn’t be holding $HIMS

The recent news is nothing new to this company. This exact same drama happened in late 2024.

Fundamentals haven’t changed.

Management hasn’t changed.

Company’s mission hasn’t changed.

If you’r

[Akash @Kajiastic]

Im very tempted to sell my $HIMS position after yesterdays drama and especially the FDA directly targeting the company for their so called malpractices.

I really love the vison and misson of the company but sometimes I think they are just not focussed on the right things.

After listening to yesterdays emergency podcast from @himshouse with @cremieuxrecueil honestly I agree that using liposomal delivery ( not tested ) vs. SNAC ( tested and FDA approved ) without doing any clinical tests might just be ripping off customers by saying its the same ingredient as Wegovy where the effectiveness would be literally none.

Would love experts to weigh in here but at the moment with a big target on the back along with the Chief of FDA's eyes on $HIMS, weakening new customers on the platform, I rather have my money in a company like $ZETA and sleep well know they are in safe hands.

Nonetheless I wouldnt sell out at these levels. I had trimmed half of my psition last year back at $47. Ill wait for a rebound and might exit unless things drastically change for the positive for $HIMS.

[Andrew Webley @asjwebly]

I’m still here 🤷‍♂️

Haven’t sold a single $HIMS share

Just been buying more.

[Midas @midascabal]

Good bye $HIMS bulls.

[Hims House @himshouse]

🚨 $HIMS OFFICIAL COMPANY STATEMENT

"LOOK FORWARD TO CONTINUING TO ENGAGE WITH US FDA TO ENSURE SAFE ACCESS TO AFFORDABLE HEALTHCARE"

"ALWAYS OPERATED WITH DEEP COMMITMENT TO SAFETY AND BEST INTERESTS OF CONSUMERS AND IN COMPLIANCE WITH APPLICABLE LAW"

[Andrew Webley @asjwebly]

We will find out Sunday if $HIMS reacts positvely to the superbowl Ad, or if the FDA News is clouding the judgement.

[Andrew Webley @asjwebly]

Despite the threats of lawsuits and legal touble with the FDA, $HIMS is still holding the 200 day MA.

It's currently respecting this level with a lot of volume, but If the selling pressure continues, it may not hold.

[Andrew Webley @asjwebly]

$HIMS is still holding $20

If it falls past $20, we could see another mass sell-off

[Andrew Webley @asjwebly]

Will $HIMS fall below $20 by Monday?

[Andrew Webley @asjwebly]

The FDA is taking action agaisnt Non-FDA-Approved GLP-1 Drugs AND specifically mentions $HIMS

$HIMS is down 10% after hours, barely holding onto the $20s

[Andrew Webley @asjwebly]

Anndddd there's another drop for $HIMS

[HHS General Counsel Mike Stuart @HHSGCMikeStuart]

Based on a review of the applicable facts, earlier today @HHSOGC referred Hims & Hers Health, Inc. (“Hims”) to the Department of Justice for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.

[Andrew Webley @asjwebly]

$HIMS "Same active ingredient as wegovy" has been removed from their marketing.

They also removed the disclosure mentioning Wegovy

[Mind Investor @mind1nvestor]

I will create the next generation of millionaires.

And I won’t need dozens of stocks to do it.

I only need one.

$HIMS

The only one who has been right, the only one everyone doubted, but here we are.

[matt @longinvest32]

$hims should be called $nvo destroyer

[Andrew Webley @asjwebly]

Just a few comments when I mentioned $HIMS has a MOAT.

I’ll circle back to this post in a year or two when $HIMS proves they have an advantage in the healthcare industry.

Some people may not be able to see it now, but $HIMS definitely has an advantage that other companies don’t

[Nicholas Ryan Gonino @nikoliasgoninus]

$HIMS investors should read more about liposomal delivery mechanisms and their effectiveness. https://t.co/psMGtq7eGM